Jasper Therapeutics, Inc. (JSPRW)
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.
Address
2200 BRIDGE PKWY SUITE #102
REDWOOD CITY, CA 94065
Founded
2018
Number of Employees
45
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
- | - | - | - | - | - | - | - | - | $661 | - | $661 |
| Average Price | - | - | - | - | - | - | - | - | - | $14.60 | - | $14.60 |
| # Shares Purchased | - | - | - | - | - | - | - | - | - | 45,293 | - | 45,293 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | - | - | 50.7% | - | 50.7% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | - | - | 31.3% | - | 31.3% |
| Excess Total Return | - | - | - | - | - | - | - | - | - | 19.4% | - | 19.4% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | - | - | 84% | - | 71% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at JSPRW make a trade.
Creating a free account takes less than one minute